12:00 AM
Apr 27, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TZP-101: Phase IIb data

Data from an adaptive, double-blind, international Phase IIb trial in 76 patients showed that IV TZP-101 missed the primary endpoint of significantly improving the postprandial fullness/early satiety subscale score of the GCSI from baseline vs. placebo, but the 80 µg/kg dose did show a trend towards meeting the endpoint (p=0.06). Patients were...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >